Overall, this is a disappointing result for AstraZeneca as it does not appear to offer any differentiation to Lipitor in high-risk patients, ahead of generic competition to the latter, starting in the USA on November 30.
Crestor is the company's biggest-selling drug (second-quarter turnover was up 20% to $1.71 billion) and better results from SATURN would have probably boosted those figures, but given these results, doctors are likely to plump for soon-to-be available cheap copies of Lipitor.
Más
Ver también:
JUPITER truena flojito...(II).
Crestor en PHARMACOSERÍAS
Entradas
No hay comentarios:
Publicar un comentario